Letrozole Tablets IP 2.5 mg

In reproductive medicine, Letrozole is commonly prescribed for ovulation induction in women with ovulatory disorders and is frequently incorporated into assisted reproductive technology (ART) and IVF protocols. It helps promote controlled follicular recruitment while maintaining a favourable hormonal environment. In oncology, Letrozole is indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women, where it helps reduce estrogen-dependent tumour growth as part of an individualised treatment plan.

Letrozole should only be used under the supervision of a qualified healthcare professional, with the dosage and duration determined according to the patient’s medical condition and treatment goals. Regular clinical monitoring may be recommended during therapy. When used as directed, Letrozole remains an established therapeutic option in both fertility management and hormone receptor-positive breast cancer treatment, providing targeted therapy based on individual patient needs.